Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population

World Journal of Gastroenterology

Volumn 19, Issue 21, 2013, Pages 3316-3323

  Fan, Xiang Shan ^a   Chen, Jie Yu ^a   Li, Chang Feng ^b   Zhang, Yi Fen ^a   Meng, Fan Qing ^a   Wu, Hong Yan ^a   Feng, An Ning ^a   Huang, Qin ^a,c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF FINANCE AND ECONOMICS   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinicopathology; Gastric cancer; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BASOLATERAL MEMBRANE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER;

EID: 84878549543     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i21.3316     Document Type: Article

References (31)

1. Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer 2012; 3: 137-144 [PMID: 22481979 DOI: 10.7150/jca.4090]
2. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 2012; 130: 2845-2856 [PMID: 21780108 DOI: 10.1002/ijc.26292]
3. Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol 2012; 46: 637-648 [PMID: 22751336 DOI: 10.1097/MCG.0b013e3182557307]
4. Hicks DG, Whitney-Miller C. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol 2011; 19: 506-508 [PMID: 22089490 DOI: 10.1097/ PAI.0b013e31822c3a0f]
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
6. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17: 5060-5070 [PMID: 21700765 DOI: 10.1158/1078-0432.CCR-10-2927]
7. Lordick F. Trastuzumab: a new treatment option for HER2- positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 2011; 7: 187-199 [PMID: 21345138 DOI: 10.2217/fon.10.178]
8. Cho EY, Srivastava A, Park K, Kim J, Lee MH, Do I, Lee J, Kim KM, Sohn TS, Kang WK, Kim S. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 2012; 44: 216-220 [PMID: 22437741 DOI: 10.1097/PAT.0b013e3283513e8b]
9. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25: 637-650 [PMID: 22222640 DOI: 10.1038/modpathol]
10. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe 2010; 31: 208-217 [PMID: 20443098 DOI: 10.1007/s00292-010-1278-1]
11. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805 [PMID: 18422971 DOI: 10.1111/j.1365-2559.2008.03028.x]
12. Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012; 43: 413-422 [PMID: 21855114 DOI: 10.1016/j.humpath.2011.05.019]
13. Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol 2012; 36: 577-582 [PMID: 22314190 DOI: 10.1097/ PAS.0b013e318244adbb]
14. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-59 [PMID: 21169738 DOI: 10.1097/PAP.0b013e3182026d72]
15. Bickenbach K, Strong VE. Comparisons of Gastric Cancer Treatments: East vs. West. J Gastric Cancer 2012; 12: 55-62 [PMID: 22792517 DOI: 10.5230/jgc.2012.12.2.55]
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging handbook. 7th ed. New York: Springer, 2009: 129-144
17. Odze J-FF RD, Boffetta P, Hofler H, Montgomery E. Spchler: Tumours of the oesophagogastric junction. In: Fred T, Bosman FC, Ralph HH, Neil DT. World Health Organization Classification of Tumours of the Digestive System. Lyon: IARC Press, 2010: 40-44
18. Zhang YF, Shi J, Yu HP, Feng AN, Fan XS, Lauwers GY, Mashimo H, Gold JS, Chen G, Huang Q. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus. World J Gastroenterol 2012; 18: 3602-3609 [PMID: 22826627 DOI: 10.3748/wjg.v18.i27.3602]
19. Huang Q, Shi J, Feng A, Fan X, Zhang L, Mashimo H, Cohen D, Lauwers G. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol 2011; 24: 138-146 [PMID: 20852593 DOI: 10.1038/modpathol.2010.183]
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook. 7th ed. New York: Springer, 2009: 145-152
21. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012; 20: 13-24 [PMID: 21617522 DOI: 10.1097/ PAI.0b013e31821c821c]
22. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18: 2833-2840 [PMID: 21468783 DOI: 10.1245/s10434-011-1695-2]
23. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, Dai D, Du W, Chen T, Chen M. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 2012; 62: 221-228 [PMID: 21927816 DOI: 10.1007/ s12013-011-9286-1]
24. Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, Romagnoli S, Bosari S. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol 2013; Epub ahead of print [PMID: 23348899 DOI: 10.1038/modpathol.2012.228]
25. Atkinson R, Mollerup J, Laenkholm AV, Verardo M, Hawes D, Commins D, Engvad B, Correa A, Ehlers CC, Nielsen KV. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysisassisted microscopy, and interobserver variation. Arch Pathol Lab Med 2011; 135: 1010-1016 [PMID: 21809992 DOI: 10.5858/2010-0462-OAR]
26. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, Sakai Y. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 2013; 16: 84-93 [PMID: 22410801 DOI: 10.1007/ s10120-012-0150-9]
27. Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011; 135: 1460-1465 [PMID: 22032573 DOI: 10.5858/arpa.2010-0541-OA]
28. Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, Han SW, Oh DY, Lee HJ, Kim TY, Kim WH, Yang HK, Bang YJ. Clinicopathologic characteristics of patients with stage III/ IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 2011; 20: 94-100 [PMID: 21532492 DOI: 10.1097/PDM.0b013e3181fc02b7]
29. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23: 2656-2662 [PMID: 22689179]
30. Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59: 832-840 [PMID: 22092394 DOI: 10.1111/j.1365-2559.2011.04017.x]
31. Huang Q, Fan X, Agoston AT, Feng A, Yu H, Lauwers G, Zhang L, Odze RD. Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients. Histopathology 2011; 59: 188-197 [PMID: 21884197 DOI: 10.1111/ j.1365-2559.2011.03924.x]